CA2573332A1 - Compositions and formulations of decitabine polymorphs and methods of use thereof - Google Patents

Compositions and formulations of decitabine polymorphs and methods of use thereof Download PDF

Info

Publication number
CA2573332A1
CA2573332A1 CA002573332A CA2573332A CA2573332A1 CA 2573332 A1 CA2573332 A1 CA 2573332A1 CA 002573332 A CA002573332 A CA 002573332A CA 2573332 A CA2573332 A CA 2573332A CA 2573332 A1 CA2573332 A1 CA 2573332A1
Authority
CA
Canada
Prior art keywords
decitabine
polymorph
endotherm
characterizable
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573332A
Other languages
English (en)
French (fr)
Inventor
Sanjeev Redkar
Rajashree Joshi-Hangal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2573332(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2573332A1 publication Critical patent/CA2573332A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002573332A 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof Abandoned CA2573332A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/890,828 2004-07-13
US10/890,828 US20060014949A1 (en) 2004-07-13 2004-07-13 Compositions and formulations of decitabine polymorphs and methods of use thereof
PCT/US2005/024676 WO2006017278A1 (en) 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2573332A1 true CA2573332A1 (en) 2006-02-16

Family

ID=35600347

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573332A Abandoned CA2573332A1 (en) 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof

Country Status (7)

Country Link
US (1) US20060014949A1 (cg-RX-API-DMAC7.html)
EP (1) EP1765076A4 (cg-RX-API-DMAC7.html)
JP (1) JP5159307B2 (cg-RX-API-DMAC7.html)
CN (1) CN101014246A (cg-RX-API-DMAC7.html)
AU (3) AU2005271814B2 (cg-RX-API-DMAC7.html)
CA (1) CA2573332A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006017278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
TWI477508B (zh) 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
CN101781347B (zh) * 2009-12-21 2012-09-12 南京卡文迪许生物工程技术有限公司 地西他滨多晶型物和药用组合物
HUE042327T2 (hu) * 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
EP2766041B1 (en) 2011-10-12 2018-12-05 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
WO2014053897A1 (en) 2012-10-01 2014-04-10 Johnson Matthey Public Limited Company Method for the purification of decitabine
CN103191144B (zh) * 2013-04-25 2014-06-18 李伟丽 一种治疗癌症的药物组合物及应用
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
JP2020535112A (ja) 2017-08-01 2020-12-03 ドイッチェス・クレープスフォルシュングスツェントルムDeutsches Krebsforschungszentrum Midh1阻害剤とdna低メチル化剤(hma)との組合せ
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
JP7089603B2 (ja) 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
AU2021260964A1 (en) 2020-04-23 2022-12-01 Pinotbio, Inc. Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof
BR112023001236A2 (pt) * 2020-07-23 2023-04-04 Southern Res Inst Polimorfos de 5-aza-4'-tio-2-desoxicitidina
CN119943194A (zh) * 2023-11-03 2025-05-06 中国石油天然气股份有限公司 一种分子筛晶胞参数确定方法和装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (cg-RX-API-DMAC7.html) * 1963-12-22
CH527207A (de) * 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
JPS5213741B2 (cg-RX-API-DMAC7.html) * 1972-05-22 1977-04-16
JPS5527077A (en) * 1978-08-16 1980-02-26 Shin Meiwa Ind Co Ltd Solids scraper for sludge dehydrator
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
ATE383355T1 (de) * 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract

Also Published As

Publication number Publication date
JP2008506690A (ja) 2008-03-06
AU2005271814B2 (en) 2010-11-11
WO2006017278A1 (en) 2006-02-16
AU2011200539A1 (en) 2011-03-03
EP1765076A1 (en) 2007-03-28
AU2011200540A1 (en) 2011-03-03
US20060014949A1 (en) 2006-01-19
CN101014246A (zh) 2007-08-08
AU2005271814A1 (en) 2006-02-16
JP5159307B2 (ja) 2013-03-06
AU2011200540A8 (en) 2011-03-10
EP1765076A4 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
AU2011200540A1 (en) Compositions and formulations of decitabine polymorphs and methods of use thereof
US6696458B2 (en) Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
US7858594B2 (en) Crystalline and amorphous forms of beta-L-2′-deoxythymidine
US20100062992A1 (en) Salts of 5-Azacytidine
US20060069060A1 (en) Salts of decitabine
CN108658983A (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
CN109311820B (zh) 2,6-二甲基嘧啶酮衍生物的盐及其用途
HK1184163A (en) Amorphous form of beta- l-2'-deoxythymidine
AU2005289513A1 (en) Salts of decitabine
AU2012202255A1 (en) Salts of 5-azacytidine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130712